JCI - Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV

Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV

Yuang-Taung Juang, Ying Wang, Elena E. Solomou, Yansong Li, Christian Mawrin, Klaus Tenbrock, Vasileios C. Kyttaris, George C. Tsokos

Published in Volume 115, Issue 4

J Clin Invest. 2005; 115(4):996–1005 doi:10.1172/JCI22854

Abstract | Full text | PDF

Options: View larger image (or click on image)

Figure 1

Characterization of a new anti–human CREM-specific antibody. (A) The new anti-CREM antibody recognizes CREM but not CREB and ATF-1. Nuclear proteins from primary T cells were resolved in SDS gel and then subjected to Western blotting with the new CREM antibody. The membrane was then stripped and blotted sequentially with anti–ATF-1 and anti-CREB antibody. The anti-CREM antibody recognizes only 1 band at the site expected for CREMα. Similarly, the anti–ATF-1 and anti-CREB antibodies recognize bands at the expected sites. (B) The new anti-CREM antibody disrupts the formation of –180 site–defined oligonucleotide/protein complex. Nuclear proteins from Jurkat T cells were incubated with the –180 oligonucleotide and 1 μl of serially diluted preimmune or immune serum. (C) Human CREM–defined peptide (amino acids 21–34), but not hnRNP-defined peptide (amino acids 263–275), blocks the ability of anti-CREM antibody to disrupt the formation of –180 site–defined oligonucleotide/protein complex. Anti-CREM serum was used at 10^–3 dilution in the presence or absence of 1 μM of the indicated peptide.